OakChart

Ardelyx Inc

ARDXHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 3:59 PM ET

3.13+0.12 (3.99%)
2026-11-11 22:13 CET
Market cap
756.63 USD m
Revenue, TTM
468.22 USD m
Net income, TTM
-55.47 USD m
Free cash flow, TTM
-15.96 USD m
EPS diluted, TTM
-0.23
P/E
-
Compare

Price

ARDX against its 20, 50 and 200-day averages
2050200beatearnings
3.004.005.006.007.0010.0M20.1MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26ARDXclose 3.1320-day 3.0850-day 3.30200-day 5.153.1352w low

62.7% under the 52-week high of 8.40 on 23 Jan 2026. 52-week low 2.80 on 9 Nov 2026. Last 15 sessions, 21.8% high to low

Volume 0.73× normal · the line is the 50-bar volume average

Profile

ARDX
52-week range, 6% of the way up
2.808.40

Ardelyx, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs. Its products include IBSRELA and XPHOZAH. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

IndexRUT
Employees489
IPOJun 19, 2014
Beta0.77
ATR, 14d0.16
Rel volume0.73
Short float12.09%
Insider own3.91%
Inst own69.92%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap786.79M
Enterprise Value757.79M
Income-55.47M
Sales468.22M
Book/sh0.65
Cash/sh1.14
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees489
IPOJun 19, 2014

Ratios

P/E-
Forward P/E16.50
PEG-
P/S1.68
P/B4.79
P/C2.76
P/FCF-
EV/EBITDA-
EV/Sales1.62
Quick Ratio3.26
Current Ratio3.45
Debt/Eq1.56
LT Debt/Eq1.55
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.23
EPS next Y0.19
EPS next Q0.03
EPS this Y26.14%
EPS next Y198.76%
EPS next 5Y-
EPS past 3/5Y15.49% 24.66%
Sales past 3/5Y98.40% 121.90%
EPS Y/Y TTM4.82%
Sales Y/Y TTM17.57%
EPS Q/Q25.00%
Sales Q/Q15.70%
EarningsNov 03 AMC
EPS/Sales Surpr.100.00% -0.26%

Ownership

Insider Own3.91%
Insider Trans-4.09%
Inst Own69.92%
Inst Trans-4.16%
ROA-10.33%
ROE-34.85%
ROIC-13.24%
Gross Margin93.80%
Oper. Margin-7.71%
Profit Margin-11.85%
SMA201.64%
SMA50-5.28%
SMA200-39.24%
Trades-

Technical

Shs Outstand251.03M
Shs Float241.54M
Short Float12.09%
Short Ratio6.48
Short Interest29.21M
52W High8.40 -62.74%
52W Low2.80 11.79%
Volatility8.07% 5.14%
ATR (14)0.16
RSI (14)49.16
Beta0.77
Rel Volume0.73
Avg Volume4.51M
Volume3,292,479

Performance

Perf Week-4.86%
Perf Month0.32%
Perf Quarter-19.95%
Perf Half Y-50.94%
Perf YTD-46.31%
Perf Year-48.94%
Perf 3Y-12.08%
Perf 5Y169.83%
Perf 10Y-80.38%
Recom1.00
Target Price12.50
Prev Close3.01
Price3.13
Change %3.99%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Jun 16, 2026ResumedLLadenburg ThalmannBuy$16+411.2%
Jan 09, 2026UpgradePPiper SandlerNeutral → Overweight
Sep 03, 2025ResumedRRaymond JamesStrong Buy$14+347.3%
Jun 18, 2025ResumedHH.C. WainwrightBuy$10+219.5%
May 02, 2025DowngradeRRaymond JamesStrong Buy → Outperform$11+251.4%
Mar 07, 2025ResumedLLadenburg ThalmannBuy
Mar 04, 2025InitiatedBBTIG ResearchBuy$14+347.3%
Nov 11, 2024DowngradeHH.C. WainwrightBuy → Neutral$11 → $5.50+75.7%
Jul 02, 2024DowngradePPiper SandlerOverweight → Neutral$15 → $7+123.6%
Apr 05, 2024InitiatedLLeerink PartnersOutperform$14+347.3%

Peers

Mkt cap
TickerCompanyMkt cap
UNCYUnicycive Therapeutics Inc105.29M
IRWDIronwood Pharmaceuticals Inc806.23M
AKBAAkebia Therapeutics Inc159.30M
CRMDCorMedix Inc413.10M
PHATPhathom Pharmaceuticals Inc510.51M
BHCBausch Health Companies Inc3.13B
FMSFresenius Medical Care AG ADR11.53B
TVTXTravere Therapeutics Inc5.00B
DVADaVita Inc11.54B
SNYSanofi ADR115.43B

Insider trading

latest 14 of 82
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Hohenleitner SusanChief Financial OfficerAug 21 '26Sale3.861,5586,009227,520Aug 25 07:19 PM
Reilly Joseph JamesSee RemarksAug 21 '26Sale3.863,98215,358145,854Aug 25 07:17 PM
Bishop John ESee RemarksAug 21 '26Sale3.8619,75076,174317,095Aug 25 07:16 PM
Brady James ParkerChief Human Resources OfficerAug 21 '26Sale3.8615,13658,378245,930Aug 25 07:15 PM
Foster Eric DuaneChief Commercial OfficerAug 21 '26Sale3.868,56233,023409,410Aug 25 07:13 PM
Kelliher MikeChief Business OfficerAug 21 '26Sale3.867,75829,922349,660Aug 25 07:11 PM
Williams Laura AChief Patient OfficerAug 21 '26Sale3.8610,73941,419367,456Aug 25 07:09 PM
RAAB MICHAELPresident & CEOAug 21 '26Sale3.8658,574225,9141,619,792Aug 25 07:07 PM
Hohenleitner SusanOfficerAug 21 '26Proposed Sale4.032,65010,680Aug 21 08:40 PM
Kelliher MikeOfficerAug 21 '26Proposed Sale4.0310,50042,315Aug 21 08:25 PM
RAAB MICHAELOfficerAug 21 '26Proposed Sale4.0344,500179,335Aug 21 08:10 PM
Williams Laura AOfficerAug 21 '26Proposed Sale4.0310,50042,315Aug 21 07:38 PM
Reilly Joseph JamesOfficerAug 21 '26Proposed Sale4.034,70018,941Aug 21 07:13 PM
Bishop John EOfficerAug 21 '26Proposed Sale4.0325,500102,765Aug 21 06:57 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
PBEInvesco Biotechnology & Genome ETFAUM: 438.02M
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
VHTVanguard Health Care ETFAUM: 21.51B
ITOTiShares Core S&P Total U.S. Stock Market ETFAUM: 95.28B

News

latest 14 of 200
  • Ardelyx to Participate at the Jefferies Global Healthcare Conference in London (GlobeNewswire)
  • Ardelyx, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ARDX (PR Newswire) -9.12%
  • Ardelyx Hits Breakeven And Holds Its Reset Guidance, But Decelerating Growth Keeps The Stock Pinned Near Lows (Earnings Whispers) +8.58%
  • Ardelyx: Q3 Earnings Snapshot (Associated Press)
  • Ardelyx Reports Third Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
  • Ardelyx Completes Enrollment in Phase 3 ACCEL Clinical Trial of IBSRELA (tenapanor) in Adults with Chronic Idiopathic Constipation (GlobeNewswire)
  • Ardelyx Must Prove Its Lowered Ibsrella Forecast Holds As Payer Hurdles Test Demand (Earnings Whispers)
  • Ardelyx Presents Real-World Data at ASN Kidney Week 2026 Showing Serum Phosphate Reductions Following XPHOZAH (tenapanor) Initiation With or Without Phosphate Binders (GlobeNewswire)
  • Ardelyx, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ARDX (PR Newswire)
  • Ardelyx to Report Third Quarter 2026 Financial Results on November 3, 2026 (GlobeNewswire)
  • ARDX Stockholders Have Rights - If You Lost Money Investing in Ardelyx, Inc. Contact Robbins LLP for Information About Recovering Your Losses (PR Newswire)
  • Ardelyx, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ARDX (PR Newswire)
  • Ardelyx Presents Real-World Data at ACG 2026 Showing Reduced Healthcare Resource Utilization Following IBSRELA Initiation in Adults with IBS-C (GlobeNewswire)
  • Ardelyx to Present New Data on Hyperphosphatemia Management at ASN Kidney Week 2026 (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-030.000-0.0160.000127.66127.9911
2026Q22026-08-06-0.070-0.066-0.067120.88121.0410
2026Q12026-04-30-0.150-0.142-0.15394.4792.7810
2025Q42026-02-190.0000.013-0.002125.22118.0511
2025Q32025-10-300.000-0.058-0.004110.33100.5412
2025Q22025-08-04-0.080-0.132-0.08097.6681.0812
2025Q12025-05-01-0.170-0.112-0.17274.1178.1511
2024Q42025-02-200.0200.0040.019116.13109.949
2024Q32024-10-310.000-0.049-0.00398.2486.6410
2024Q22024-08-01-0.070-0.106-0.07073.2255.0310
2024Q12024-05-02-0.110-0.147-0.11446.0236.4010
2023Q42024-02-22-0.120-0.095-0.12434.3634.069
2023Q32023-10-310.030-0.1080.02956.3922.578
2023Q22023-08-02-0.080-0.115-0.08022.3315.287
2023Q12023-05-03-0.130-0.101-0.12911.3710.417
2022Q42023-03-020.0600.0020.05544.1823.186

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-1.470-1.489-1.4725.283.75
2020FY-1.050-0.999-1.0537.576.92
2021FY-1.520-1.514-1.51810.109.75
2022FY-0.420-0.508-0.42452.1634.15
2023FY-0.300-0.272-0.301124.46124.2
2024FY-0.170-0.172-0.166333.62327.38
2025FY-0.260-0.243-0.260407.32400.15
2026FY--0.192--482.24
2027FY-0.190--608.01
2028FY-0.793--821.58
2029FY-1.300--1,051
2030FY-1.740--1,236

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-041137139.23129.87148.55
2026Q4S2026-11-031113142.23136150.09
2026Q4S2026-10-291113142.23136150.09
2026Q4S2026-10-281112143.14136154.3
2026Q4S2026-10-211113143.14136154.3
2026Q4S2026-10-2011110143.14136154.3
2026Q4S2026-10-1611110143.9136154.3
2026Q4S2026-10-0211110144.33135.76154.3
2026Q4S2026-09-0811011144.19135.76154.3
2026Q4S2026-08-1711011144.19135.76154.3
2026Q4S2026-08-1411011144.44135.76154.59
2026Q4S2026-08-0910010145.26135.76154.59
2026Q4S2026-08-0711010147.94135.76174.78
2026Q4S2026-08-041140175.75158.1203.2

Estimate history

EPS, annual-1.36-1.624-1.472-1.053-1.518-0.424-0.301-0.166-0.256-0.225
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.0030.019-0.172-0.08-0.004-0.002-0.153-0.067-0.003
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual422.6075.2817.57110.09752.158124.456333.615407.32468.22
Period201720182019202020212022202320242025TTM
Sales, quarterly98.241116.12974.11497.662110.329125.21594.473120.877127.655
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual47.53562.51788.81893.6130.183198.575232.453238.016244.352251.031
Period201720182019202020212022202320242025MRQ
Shares, quarterly236.89238.016239.201240.766242.972244.352246.973249.147251.031
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue468.22407.32333.62124.4652.1610.107.575.282.61
Cost of Goods Sold Incl. D&A29.0242.6052.6219.098.725.534.124.943.14
Gross Profit439.20364.72281.00105.3743.444.573.460.34-0.54
Selling, General and Administrative Excl. Other475.30405.70308.95168.65107.20158.9294.2391.6090.41
Research and Development91.2868.4750.2534.2434.0689.7063.2369.1869.37
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-36.10-40.98-27.95-63.28-63.76-154.35-90.78-91.26-90.95
Interest Expense28.1028.4020.098.875.074.505.105.733.53
Unusual Expense0.000.000.330.000.000.000.00--
Net Income Before Taxes-55.26-60.63-38.87-65.52-67.20-158.16-94.31-94.64-91.29
Income Taxes0.210.970.270.550.010.000.000.300.00
Consolidated Net Income-55.47-61.60-39.14-66.07-67.21-158.16-94.31-94.94-91.30
Net Income From Continuing Operations-55.47-61.60-39.14-66.07-67.21-158.16-94.31-94.94-91.30
Net Income-55.47-61.60-39.14-66.07-67.21-158.16-94.31-94.94-91.30
EPS (Recurring)-0.22-0.26-0.17-0.30-0.42-1.52-1.05-1.47-1.62
EPS (Basic, Before Extraordinaries)-0.23-0.26-0.17-0.30-0.42-1.52-1.05-1.47-1.62
EPS (Diluted)-0.23-0.26-0.17-0.30-0.42-1.52-1.05-1.47-1.62
EBITDA-33.03-37.92-25.89-61.98-59.16-149.82-86.81-86.92-88.27
Non-Operating Income (Expense)8.948.749.506.631.630.691.572.353.19
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense45.0538.6829.5310.698.498.797.737.257.29
Price To Sales Ratio1.833.453.5710.938.6711.3576.5591.6338.60
Gross Margin93.8089.5484.2384.6683.2945.2745.636.46-20.60
Operating Margin-7.71-10.06-8.38-50.84-122.24-1,528.63-1,199.05-1,728.14-3,488.57
Net Margin-11.85-15.12-11.73-53.08-128.85-1,566.46-1,245.71-1,797.77-3,502.03
Shares Outstanding251.03244.35238.02232.45198.58130.1893.6088.8262.52
Market Capitalization756.63756.631,200.851,439.26534.26124.02583.91643.98111.22

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue127.66120.8894.47125.22110.3397.6674.11116.13
Cost of Goods Sold Incl. D&A5.166.365.7311.774.8913.0312.9018.78
Gross Profit122.50114.5188.75113.44105.4484.6361.2197.35
Selling, General and Administrative Excl. Other118.47126.94121.54108.35100.7799.0297.5689.22
Research and Development24.5825.5019.2721.9317.1615.0414.3413.15
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income4.02-12.43-32.795.104.67-14.39-36.358.12
Interest Expense7.386.226.927.587.986.586.265.85
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-0.65-16.61-37.60-0.40-0.87-19.08-40.284.68
Income Taxes0.090.110.010.010.100.000.860.04
Consolidated Net Income-0.74-16.72-37.60-0.41-0.97-19.08-41.144.64
Net Income From Continuing Operations-0.74-16.72-37.60-0.41-0.97-19.08-41.144.64
Net Income-0.74-16.72-37.60-0.41-0.97-19.08-41.144.64
EPS (Recurring)-0.00-0.07-0.15-0.00-0.00-0.08-0.170.02
EPS (Basic, Before Extraordinaries)-0.00-0.07-0.15-0.00-0.00-0.08-0.170.02
EPS (Diluted)-0.00-0.07-0.15-0.00-0.00-0.08-0.170.02
EBITDA4.64-11.82-31.886.025.57-13.76-35.758.64
Non-Operating Income (Expense)2.712.042.112.082.451.892.332.41
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense11.9312.1011.189.8310.079.239.557.79
Price To Sales Ratio1.832.813.443.493.352.443.243.71
Gross Margin95.9694.7493.9490.6095.5786.6582.5983.83
Operating Margin3.15-10.28-34.714.074.23-14.74-49.047.00
Net Margin-0.58-13.83-39.81-0.33-0.88-19.54-55.514.00
Shares Outstanding251.03249.15246.97244.35242.97240.77239.20238.02
Market Capitalization756.631,259.851,469.031,416.541,327.82937.881,170.331,200.85

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments264.69250.10184.30123.91116.69186.48247.51168.09133.98
Short Term Receivables71.8557.7022.037.730.500.000.755.0810.80
Inventories17.7321.1712.453.280.000.000.000.000.00
Other Current Assets28.0527.4727.3318.6816.468.203.803.204.94
Total Current Assets382.32356.45246.11153.60133.65194.69252.06176.37149.71
Net Property, Plant & Equipment6.983.886.6010.5215.114.217.415.618.03
Total Investments and Advances0.000.000.000.000.002.110.000.000.00
Deferred Tax Assets1.20--------
Other Assets112.3175.4344.8725.951.150.550.311.350.16
Total Assets502.81435.75297.58190.07149.91201.56259.78183.33157.90
Short Term Debt Incl. Current Port. of LT Debt1.481.564.4330.6135.766.283.790.000.00
Accounts Payable19.2316.0011.1410.864.285.632.191.153.93
Other Current Liabilities67.8960.2734.8224.1412.7916.5116.2416.5813.94
Total Current Liabilities88.6177.8350.3965.6052.8228.4222.2217.7317.87
Long Term Debt206.47151.8851.5517.119.7547.0350.9149.210.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities1.20--------
Other Liabilities39.5832.7628.829.034.730.000.000.580.72
Total Liabilities335.86262.46130.7691.7467.3075.4573.1367.5218.59
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity166.95173.29166.8298.3382.62126.11186.66115.81139.31
Total Shareholders Equity166.95173.29166.8298.3382.62126.11186.66115.81139.31
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity166.95173.29166.8298.3382.62126.11186.66115.81139.31
Total Liabilities & Stockholders Equity502.81435.75297.58190.07149.91201.56259.78183.33157.90
Book Value Per Share0.680.730.720.500.631.352.101.852.93
Tangible Book Value Per Share0.680.730.720.500.631.352.101.852.93
Full-Time Employees48939526713386129888675
Price to Book Ratio4.617.597.537.991.734.803.570.972.48
Return on Assets-13.13-10.67-27.10-39.54-90.00-40.89-42.85-53.51-34.68
Return on Equity-36.21-23.01-49.83-74.28-151.55-60.31-62.78-71.57-38.70
Return on Invested Capital-16.50-12.04-30.26-58.22-171.24-54.47-39.96-55.32-46.18
Quick Ratio4.114.314.642.292.536.8511.349.958.38
Current Ratio4.314.584.882.342.536.8511.349.958.38

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-55.47-61.60-39.14-66.07-67.21-158.16-94.31-94.94-91.30
Depreciation3.063.062.061.294.604.533.974.342.68
Other Funds (Non Cash)59.6247.4141.4318.4412.1413.0112.1211.138.99
Funds from Operations7.21-11.134.36-46.33-50.47-140.63-78.22-79.47-79.63
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-22.72-31.35-49.17-43.39-19.57-11.92-3.212.989.35
Cash from Operating Activities-15.51-42.48-44.81-89.72-70.04-152.55-81.44-76.48-70.27
Capital Expenditures-0.44-1.49-1.01-0.34-0.06-1.87-0.32-0.33-0.31
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.000.000.000.001.800.000.000.00-
Purchase or Sale of Investments-37.12-7.47-17.31-130.9016.6752.81-31.1223.70-29.58
Purchase of Investments-250.65-218.92-195.16-215.22-50.33-72.73-150.85-102.67-169.03
Sale Or Maturity of Investments213.53211.46177.8584.3267.00125.55119.73126.37139.45
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-37.56-8.96-18.32-131.2518.4150.95-31.4423.37-29.89
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock8.645.848.14120.4171.83102.5522.90155.4854.26
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock8.645.848.14120.4171.83102.5522.90155.4854.26
Proceedsfrom Stock Options0.000.000.00119.2471.62101.1521.05154.9053.77
Issuance or Reduction of Debt, Net48.0448.6798.4525.893.51-19.44-0.120.0049.29
Change in Long Term Debt48.0448.6798.4525.893.51-19.44-0.120.0049.29
Issuance of Long Term Debt81.8748.6799.4527.3936.550.000.000.0049.29
Reduction of Long Term Debt-33.830.00-1.00-1.50-33.04-19.44-0.120.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.00-0.110.000.000.00
Other Financing Activities Uses0.000.000.000.000.00-0.110.000.000.00
Cash from Financing Activities56.6854.51106.59146.2975.3483.0022.78155.48103.55
Net Change in Cash3.603.0743.46-74.6723.71-18.60-90.10102.363.38
Free Cash Flow-15.96-43.98-45.82-90.06-70.10-154.42-81.76-76.81-70.58
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments285.34281.83238.07264.69242.71238.45
Short Term Receivables93.44100.3582.8471.8576.6162.55
Inventories24.4425.8622.7517.7325.1722.27
Other Current Assets38.1733.8938.2128.0523.5028.29
Total Current Assets441.39441.93381.87382.32367.99351.57
Net Property, Plant & Equipment5.265.856.436.987.227.15
Total Investments and Advances0.000.000.000.000.000.00
Deferred Tax Assets---1.20--
Other Assets140.88128.12116.20112.31110.96108.05
Total Assets587.52575.89504.51502.81486.17466.77
Short Term Debt Incl. Current Port. of LT Debt1.581.541.511.481.441.18
Accounts Payable33.6638.4128.2019.2318.3921.68
Other Current Liabilities92.5792.2779.8667.8963.5658.85
Total Current Liabilities127.81132.22109.5788.6183.3981.72
Long Term Debt254.76254.65206.75206.47206.18205.46
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities---1.20--
Other Liabilities40.9140.0239.5639.5842.3340.06
Total Liabilities423.48426.88355.88335.86331.89327.24
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity164.05149.01148.62166.95154.28139.53
Total Shareholders Equity164.05149.01148.62166.95154.28139.53
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity164.05149.01148.62166.95154.28139.53
Total Liabilities & Stockholders Equity587.52575.89504.51502.81486.17466.77
Book Value Per Share0.650.600.600.680.630.58
Tangible Book Value Per Share0.650.600.600.680.630.58
Full-Time Employees---489--
Price to Book Ratio4.618.478.779.189.516.44
Return on Assets-10.33-10.68-12.69-13.13-13.24-13.92
Return on Equity-34.85-38.61-39.46-36.21-36.18-39.36
Return on Invested Capital-0.18-4.14-10.58-0.11-0.27-5.53
Quick Ratio3.263.153.284.114.114.03
Current Ratio3.453.343.494.314.414.30

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-0.74-16.72-37.60-0.41-0.97-19.08
Depreciation0.620.600.920.920.910.63
Other Funds (Non Cash)15.9516.0614.8412.779.6712.04
Funds from Operations15.83-0.06-21.8513.299.61-6.41
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-13.66-6.34-10.387.67-9.24-18.93
Cash from Operating Activities2.17-6.40-32.2420.950.36-25.34
Capital Expenditures0.00-0.01-0.07-0.36-0.16-0.65
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments-54.0022.67-9.934.14-50.3535.57
Purchase of Investments-118.03-33.89-47.88-50.86-113.70-22.81
Sale Or Maturity of Investments64.0356.5637.9555.0063.3558.38
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-54.0022.66-9.993.78-50.5134.92
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.961.685.440.562.810.99
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.961.685.440.562.810.99
Proceedsfrom Stock Options0.000.000.000.000.000.00
Issuance or Reduction of Debt, Net0.0048.040.000.000.0048.67
Change in Long Term Debt0.0048.040.000.000.0048.67
Issuance of Long Term Debt0.0081.870.000.000.0048.67
Reduction of Long Term Debt0.00-33.830.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities0.9649.725.440.562.8149.66
Net Change in Cash-50.8765.98-36.7925.28-47.3359.24
Free Cash Flow2.17-6.41-32.3120.590.21-25.99

Revenue breakdown

License2024: 78.00K 2025: 5.09M
Non-Cash Royalty Related To Sale of Future Royalties2024: 2.69M 2025: 8.55M
Product Supply2024: 11.65M 2025: 15.88M
Product, IBSRELA2024: 158.29M 2025: 274.21M
Product, XPHOZAH2024: 160.91M 2025: 103.60M
Asia Pacific2024: 14.34M 2025: 29.17M
North America2024: 78.00K 2025: 342.00K
United States2024: 319.20M 2025: 377.81M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3012.09%29.2M241.5M4.56M
2026-10-1512.63%30.2M239.4M4.29M
2026-09-3011.56%27.7M239.4M4.04M
2026-09-1510.69%25.6M239.4M4.38M
2026-08-319.49%22.7M239.4M4.22M
2026-08-149.38%22.4M239.2M4.05M
2026-07-3110.97%26.2M239.2M3.84M
2026-07-1511.07%26.2M237.2M4.01M
2026-06-3010.70%25.4M237.1M4.01M
2026-06-1511.37%26.9M237.0M3.55M
2026-05-2910.48%24.8M236.3M3.52M
2026-05-1510.09%23.9M236.3M4.01M
2026-04-309.98%23.6M236.2M3.64M
2026-04-1510.23%24.0M234.8M3.94M
2026-03-3110.41%24.5M234.9M4.77M
2026-03-139.24%21.7M234.9M4.61M
2026-02-279.31%21.9M234.9M4.53M
2026-02-138.74%20.5M234.9M4.07M
2026-01-307.97%18.6M232.8M4.41M
2026-01-159.33%21.8M233.9M4.12M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call0.500.504.702.520.0005.000.000.980-0.0110.000
call1.000.702.801.9816.54413.000.000.942-0.0230.001
call1.500.002.301.5510.79815.000.000.909-0.0230.001
call2.000.452.451.0512.35349.000.000.865-0.0210.001
call2.500.151.100.444.3435.000.000.795-0.0180.001
call3.000.150.300.202.27529952.000.620-0.0150.002
call3.500.000.050.030.8569160.000.222-0.0070.001
call4.000.000.050.011.4795200.000.147-0.0090.001
call4.500.000.100.001.8180.000.000.127-0.0100.001
call5.000.000.050.032.1985.000.000.110-0.0100.001
call5.500.000.950.012.4701.000.000.102-0.0120.001
call6.000.000.050.032.7872.000.000.094-0.0120.001
call7.000.000.050.033.18330.000.000.085-0.0130.001
put0.500.000.050.007.8330.000.00-0.021-0.0100.000
put1.000.001.750.007.2420.000.00-0.059-0.0230.001
put1.500.000.950.005.0240.000.00-0.091-0.0230.001
put2.000.001.750.053.4681500.00-0.135-0.0210.001
put2.500.001.750.012.2353180.00-0.205-0.0170.001
put3.000.000.150.051.10550020,001-0.369-0.0120.002
put3.500.000.850.353.1981.000.00-0.778-0.0070.001
put4.000.402.350.009.3240.000.00-0.845-0.0090.001
put4.500.102.850.009.8370.000.00-0.873-0.0100.001
put5.000.603.700.0012.4580.000.00-0.888-0.0110.001
put5.501.004.500.0014.9790.000.00-0.898-0.0120.001
put6.001.805.000.0013.8100.000.00-0.906-0.0120.001
put7.003.204.803.678.6030.000.00-0.915-0.0130.001

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-0310-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-038-KCurrent report2026-11-03SEC
2026-08-254Statement of changes in beneficial ownership of securities2026-08-21SEC
2026-08-254Statement of changes in beneficial ownership of securities2026-08-21SEC
2026-08-254Statement of changes in beneficial ownership of securities2026-08-21SEC
2026-08-254Statement of changes in beneficial ownership of securities2026-08-21SEC
2026-08-254Statement of changes in beneficial ownership of securities2026-08-21SEC
2026-08-254Statement of changes in beneficial ownership of securities2026-08-21SEC
2026-08-254Statement of changes in beneficial ownership of securities2026-08-21SEC
2026-08-254Statement of changes in beneficial ownership of securities2026-08-21SEC
2026-08-21144Filing for proposed sale of securities under Rule 144.SEC
2026-08-21144Filing for proposed sale of securities under Rule 144.SEC
2026-08-21144Filing for proposed sale of securities under Rule 144.SEC
2026-08-21144Filing for proposed sale of securities under Rule 144.SEC
2026-08-21144Filing for proposed sale of securities under Rule 144.SEC
2026-08-21144Filing for proposed sale of securities under Rule 144.SEC
2026-08-21144Filing for proposed sale of securities under Rule 144.SEC
2026-08-21144Filing for proposed sale of securities under Rule 144.SEC
2026-08-178-KCurrent report2026-08-11SEC
2026-08-14SCHEDULE 13GSEC
2026-08-11SCHEDULE 13G/ASEC
2026-08-10S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-08-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-068-KCurrent report2026-08-06SEC
2026-07-174Statement of changes in beneficial ownership of securities2026-07-15SEC
2026-07-028-KCurrent report2026-06-29SEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-18SEC
2026-06-18144Filing for proposed sale of securities under Rule 144.SEC
2026-06-184Statement of changes in beneficial ownership of securities2026-06-16SEC
2026-06-184Statement of changes in beneficial ownership of securities2026-06-16SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-0800486.20K8
2026-0700210.92K1
2026-0600726.83K2
2026-0500802.55K9
2026-0400261.95K1
2026-0300243.33K1
2026-021.95M1768.92K9
2026-0100348.90K1
2025-120000
2025-1100452.74K6

Institutional holders

Manager% owned
BlackRock, Inc.9.51%
Rubric Capital Management LP6.56%
MILLENNIUM MANAGEMENT LLC5.63%
STATE STREET CORP5.41%
VANGUARD CAPITAL MANAGEMENT LLC4.24%
NOMURA ASSET MANAGEMENT INTERNATIONAL INC.3.86%
VANGUARD PORTFOLIO MANAGEMENT LLC3.25%
GEODE CAPITAL MANAGEMENT, LLC2.49%
Jupiter Topco LLC2.15%
TWO SIGMA INVESTMENTS, LP2.11%

Funds

Fund% owned
Nomura Small Cap Core Fund3.06%
State Street(R) SPDR(R) S&P(R) Biotech ETF3.00%
VANGUARD TOTAL STOCK MARKET INDEX FUND3.00%
iShares Russell 2000 ETF2.58%
VANGUARD EXTENDED MARKET INDEX FUND1.15%
VANGUARD STRATEGIC EQUITY FUND1.09%
Fidelity Small Cap Index Fund1.08%
iShares Russell 2000 Growth ETF0.91%
Janus Henderson Global Life Sciences Fund0.88%
BlackRock Advantage Small Cap Core Fund0.66%

OakChart. ARDX. Cached 15 minutes.